GGHC
UTHR icon

Gilder Gagnon Howe & Co’s United Therapeutics UTHR Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-7,140
Closed -$1.6M – 340
2023
Q1 		$1.6M Buy
7,140
+2,689
+60% +$663K 0.03% 185
2022
Q4 		$1.24M Buy
+4,451
New +$1.12M 0.02% 192

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Gilder Gagnon Howe & Co's UTHR Position: Q2 2023 in Review

Gilder Gagnon Howe & Co sold out of United Therapeutics (UTHR) in Q2 2023, closing a stake of 7,140 shares — an estimated $1.6M sold.

Gilder Gagnon Howe & Co first reported a position in UTHR in Q4 2022 and held it in 2 quarters. The position peaked at $1.6M in Q1 2023. 473 funds tracked by Wall St. Rank hold UTHR as of Q2 2023.

  • Gilder Gagnon Howe & Co reported no remaining United Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 7,140 United Therapeutics shares in Q2 2023, an estimated $1.6M.
  • Gilder Gagnon Howe & Co first reported a position in United Therapeutics in Q4 2022 and held it in 2 quarters.
  • Gilder Gagnon Howe & Co's United Therapeutics position peaked at $1.6M in Q1 2023.
  • 473 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2023.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2023, filed 14 Aug 2023.